292966625	292966625	CD	B-NP	O
|	|	NN	I-NP	O
GH	GH	NN	I-NP	O
|	|	NN	I-NP	O
92601581	92601581	CD	I-NP	O
|	|	NN	I-NP	O
|	|	NN	I-NP	O
9538686	9538686	CD	B-NP	O
|	|	CC	I-NP	O
1/24/2006	1/24/2006	CD	I-NP	O
12	12	CD	I-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
AM	AM	VBP	B-VP	O
|	|	JJ	B-NP	B-protein
ABDOMINAL	ABDOMINAL	NNP	I-NP	I-protein
PAIN	PAIN	NNP	I-NP	I-protein
|	|	NNP	I-NP	O
Unsigned	Unsigned	NNP	I-NP	O
|	|	NNP	I-NP	O
DIS	DIS	NNP	I-NP	O
|	|	NNP	I-NP	O
Admission	Admission	NNP	I-NP	O
Date	Date	NNP	I-NP	O
:	:	:	O	O
8/19/2006	8/19/2006	CD	B-NP	O
Report	Report	NNP	I-NP	O
Status	Status	NNP	I-NP	O
:	:	:	O	O
Unsigned	Unsigned	NNP	B-NP	O
Discharge	Discharge	NNP	I-NP	O
Date	Date	NNP	I-NP	O
:	:	:	O	O
6/1/2006	6/1/2006	CD	B-NP	O
ATTENDING	ATTENDING	NN	I-NP	O
:	:	:	O	O
DRISCOLL	DRISCOLL	NN	B-NP	O
,	,	,	O	O
ELDEN	ELDEN	NNP	B-NP	O
MD	MD	NNP	I-NP	O
SERVICE	SERVICE	NNP	I-NP	O
:	:	:	O	O
GMS	GMS	NNP	B-NP	O
Katena	Katena	NNP	I-NP	O
Highway	Highway	NNP	I-NP	O
PRIMARY	PRIMARY	NNP	I-NP	O
CARE	CARE	NNP	I-NP	O
PHYSICIAN	PHYSICIAN	NNP	I-NP	O
:	:	:	O	O
Chet	Chet	NNP	B-NP	O
Nerpio	Nerpio	NNP	I-NP	O
,	,	,	O	O
M.D.	M.D.	NNP	B-NP	O
PRINCIPAL	PRINCIPAL	NNP	I-NP	O
DIAGNOSES	DIAGNOSES	NNP	I-NP	O
:	:	:	O	O
End-stage	End-stage	JJ	B-NP	O
renal	renal	JJ	I-NP	O
disease	disease	NN	I-NP	O
and	and	CC	O	O
osteomyelitis	osteomyelitis	NN	B-NP	O
.	.	.	O	O

LIST	LIST	NN	B-NP	O
OF	OF	IN	B-PP	O
OTHER	OTHER	NNP	B-NP	O
PROBLEMS	PROBLEMS	NNP	I-NP	O
AND	AND	CC	O	O
DIAGNOSES	DIAGNOSES	NNP	B-NP	O
:	:	:	O	O
Insulin-dependent	Insulin-dependent	JJ	B-NP	O
diabetes	diabetes	NN	I-NP	O
mellitus	mellitus	NN	I-NP	O
,	,	,	O	O
peripheral	peripheral	JJ	B-NP	O
neuropathy	neuropathy	NN	I-NP	O
,	,	,	O	O
left	leave	VBD	B-VP	O
Charcot	Charcot	NNP	B-NP	O
foot	foot	NN	I-NP	O
complicated	complicate	VBN	B-VP	O
by	by	IN	B-PP	O
ulceration	ulceration	NN	B-NP	O
requiring	require	VBG	B-VP	O
partial	partial	JJ	B-NP	O
thickness	thickness	NN	I-NP	O
debridement	debridement	NN	I-NP	O
on	on	IN	B-PP	O
3/26/06	3/26/06	CD	B-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
setting	setting	NN	I-NP	O
of	of	IN	B-PP	O
new	new	JJ	B-NP	O
Aircast	Aircast	NN	I-NP	O
started	start	VBN	B-VP	O
on	on	IN	B-PP	O
8/21/06	8/21/06	CD	B-NP	O
now	now	RB	B-ADVP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
cast	cast	NN	I-NP	O
applied	apply	VBN	B-VP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
left	left	JJ	I-NP	O
foot	foot	NN	I-NP	O
,	,	,	O	O
hypertension	hypertension	NN	B-NP	O
,	,	,	O	O
chronic	chronic	JJ	B-NP	O
renal	renal	JJ	I-NP	O
insufficiency	insufficiency	NN	I-NP	O
,	,	,	O	O
hyperlipidemia	hyperlipidemia	NN	B-NP	O
,	,	,	O	O
spinal	spinal	JJ	B-NP	O
stenosis	stenosis	NN	I-NP	O
,	,	,	O	O
anemia	anemia	NN	B-NP	O
of	of	IN	B-PP	O
chronic	chronic	JJ	B-NP	O
disease	disease	NN	I-NP	O
,	,	,	O	O
thrombocytopenia	thrombocytopenia	NN	B-NP	O
,	,	,	O	O
and	and	CC	O	O
ascus	ascus	NN	B-NP	O
6/10	6/10	CD	I-NP	O
and	and	CC	I-NP	O
11/6	11/6	CD	I-NP	O
BRIEF	BRIEF	NN	I-NP	O
HISTORY	HISTORY	NN	I-NP	O
OF	OF	IN	B-PP	O
PRESENT	PRESENT	JJ	B-NP	O
ILLNESS	ILLNESS	NN	I-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
is	be	VBZ	B-VP	O
a	a	DT	B-NP	O
58-year-old	58-year-old	JJ	I-NP	O
female	female	NN	I-NP	O
with	with	IN	B-PP	O
chronic	chronic	JJ	B-NP	O
renal	renal	JJ	I-NP	O
insufficiency	insufficiency	NN	I-NP	O
,	,	,	O	O
baseline	baseline	NN	B-NP	O
creatinine	creatinine	NN	I-NP	O
3.8	3.8	CD	I-NP	O
,	,	,	O	O
diabetes	diabetes	NN	B-NP	O
mellitus	mellitus	NN	I-NP	O
,	,	,	O	O
hypertension	hypertension	NN	B-NP	O
,	,	,	O	O
and	and	CC	O	O
anemia	anemia	NN	B-NP	O
,	,	,	O	O
who	who	WP	B-NP	O
present	present	VBP	B-VP	O
with	with	IN	B-PP	O
two	two	CD	B-NP	O
weeks	week	NNS	I-NP	O
of	of	IN	B-PP	O
diffuse	diffuse	JJ	B-NP	B-protein
abdominal	abdominal	JJ	I-NP	I-protein
pain	pain	NN	I-NP	I-protein
that	that	WDT	B-NP	O
acutely	acutely	RB	B-ADVP	O
worsened	worsen	VBD	B-VP	O
one	one	CD	B-NP	O
day	day	NN	I-NP	O
prior	prior	JJ	B-ADJP	O
to	to	TO	B-PP	O
admission	admission	NN	B-NP	O
with	with	IN	B-PP	O
associated	associate	VBN	B-NP	O
nausea	nausea	NN	I-NP	O
,	,	,	O	O
nonbloody	nonbloody	JJ	B-NP	O
emesis	emesis	NN	I-NP	O
,	,	,	O	O
and	and	CC	O	O
chills	chill	NNS	B-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
found	find	VBN	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
febrile	febrile	JJ	B-ADJP	O
with	with	IN	B-PP	O
leukocytosis	leukocytosis	NN	B-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
ED	ED	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
had	have	VBD	B-VP	O
been	be	VBN	I-VP	O
seen	see	VBN	I-VP	O
previously	previously	RB	B-ADVP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
ED	ED	NN	I-NP	O
on	on	IN	B-PP	O
10/11/06	10/11/06	CD	B-NP	O
at	at	IN	B-PP	O
which	which	WDT	B-NP	O
time	time	NN	I-NP	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
treated	treat	VBN	I-VP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
UTI	UTI	NN	I-NP	B-DNA
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
sent	send	VBN	I-VP	O
home	home	NN	B-ADVP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
seven-day	seven-day	JJ	I-NP	O
course	course	NN	I-NP	O
of	of	IN	B-PP	O
ciprofloxacin	ciprofloxacin	NN	B-NP	O
and	and	CC	I-NP	O
oxycodone	oxycodone	NN	I-NP	O
for	for	IN	B-PP	O
pain	pain	NN	B-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
ciprofloxacin	ciprofloxacin	NN	I-NP	O
was	be	VBD	B-VP	O
renally	renally	RB	I-VP	O
dosed	dose	VBN	I-VP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
reports	report	VBZ	B-VP	O
that	that	IN	B-SBAR	O
she	she	PRP	B-NP	O
stopped	stop	VBD	B-VP	O
taking	take	VBG	I-VP	O
oxycodone	oxycodone	NN	B-NP	O
and	and	CC	I-NP	O
ciprofloxacin	ciprofloxacin	NN	I-NP	O
.	.	.	O	O

After	After	IN	B-PP	O
developing	develop	VBG	B-VP	O
constipation	constipation	NN	B-NP	O
,	,	,	O	O
it	it	PRP	B-NP	O
is	be	VBZ	B-VP	O
unclear	unclear	JJ	B-ADJP	O
if	if	IN	B-SBAR	O
she	she	PRP	B-NP	O
completed	complete	VBD	B-VP	O
her	her	PRP$	B-NP	O
full	full	JJ	I-NP	O
course	course	NN	I-NP	O
of	of	IN	B-PP	O
antibiotics	antibiotic	NNS	B-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
currently	currently	RB	B-ADVP	O
present	present	VBP	B-VP	O
with	with	IN	B-PP	O
complaints	complaint	NNS	B-NP	O
of	of	IN	B-PP	O
diarrhea	diarrhea	NN	B-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
setting	setting	NN	I-NP	O
of	of	IN	B-PP	O
having	have	VBG	B-VP	O
taken	take	VBN	I-VP	O
laxative	laxative	NN	B-NP	O
at	at	IN	B-PP	O
home	home	NN	B-NP	O
.	.	.	O	O

No	No	DT	B-NP	O
melena	melena	NN	I-NP	O
or	or	CC	I-NP	O
hematochezia	hematochezia	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
pain	pain	NN	I-NP	O
is	be	VBZ	B-VP	O
not	not	RB	O	O
related	related	JJ	B-ADJP	O
to	to	TO	B-PP	O
food	food	NN	B-NP	O
,	,	,	O	O
urination	urination	NN	B-NP	O
,	,	,	O	O
or	or	CC	O	O
defecation	defecation	NN	B-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
has	have	VBZ	B-VP	O
poor	poor	JJ	B-NP	O
p.o.	p.o.	FW	I-NP	O
intake	intake	NN	I-NP	O
,	,	,	O	O
denies	deny	VBZ	B-VP	O
any	any	DT	B-NP	O
sick	sick	JJ	I-NP	O
contacts	contact	NNS	I-NP	O
at	at	IN	B-PP	O
home	home	NN	B-NP	O
.	.	.	O	O

No	No	DT	B-NP	O
recent	recent	JJ	I-NP	O
travel	travel	NN	I-NP	O
.	.	.	O	O

REVIEW	REVIEW	NNP	B-NP	O
OF	OF	IN	B-PP	O
SYSTEMS	SYSTEMS	NNP	B-NP	O
:	:	:	O	O
Positive	Positive	JJ	B-ADJP	O
for	for	IN	B-PP	O
blood	blood	NN	B-NP	O
sugars	sugar	NNS	I-NP	O
ranging	range	VBG	B-VP	O
from	from	IN	B-PP	O
180-190	180-190	CD	B-NP	O
,	,	,	O	O
although	although	IN	B-SBAR	O
she	she	PRP	B-NP	O
had	have	VBD	B-VP	O
a	a	DT	B-NP	O
blood	blood	NN	I-NP	O
sugar	sugar	NN	I-NP	O
of	of	IN	B-PP	O
499	499	CD	B-NP	O
on	on	IN	B-PP	O
the	the	DT	B-NP	O
morning	morning	NN	I-NP	O
of	of	IN	B-PP	O
admission	admission	NN	B-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
has	have	VBZ	B-VP	O
fatigue	fatigue	NN	B-NP	O
but	but	CC	O	O
no	no	DT	B-NP	O
myalgias	myalgia	NNS	I-NP	O
,	,	,	O	O
no	no	DT	B-NP	O
cough	cough	NN	I-NP	O
,	,	,	O	O
chest	chest	NN	B-NP	O
pain	pain	NN	I-NP	O
,	,	,	O	O
shortness	shortness	NN	B-NP	O
of	of	IN	B-PP	O
breath	breath	NN	B-NP	O
,	,	,	O	O
no	no	DT	B-NP	O
dysuria	dysuria	NN	I-NP	O
.	.	.	O	O

In	In	IN	B-PP	O
the	the	DT	B-NP	O
ED	ED	NN	I-NP	O
,	,	,	O	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
given	give	VBN	I-VP	O
ampicillin	ampicillin	NN	B-NP	O
2	2	CD	I-NP	O
g	g	NN	I-NP	O
IV	IV	CD	B-NP	O
,	,	,	O	O
gentamicin	gentamicin	NN	B-NP	O
80	80	CD	I-NP	O
mg	mg	NN	I-NP	O
IV	IV	CD	B-NP	O
,	,	,	O	O
Flagyl	Flagyl	NN	B-NP	O
500	500	CD	I-NP	O
mg	mg	NN	I-NP	O
IV	IV	CD	B-NP	O
and	and	CC	I-NP	O
8	8	CD	I-NP	O
units	unit	NNS	I-NP	O
of	of	IN	B-PP	O
insulin	insulin	NN	B-NP	B-protein
.	.	.	O	O

ALLERGIES	ALLERGIES	NNS	B-NP	O
:	:	:	O	O
Medication	Medication	NN	B-NP	O
reaction	reaction	NN	I-NP	O
,	,	,	O	O
she	she	PRP	B-NP	O
has	have	VBZ	B-VP	O
an	an	DT	B-NP	O
allergy	allergy	NN	I-NP	O
to	to	TO	B-VP	O
lisinopril	lisinopril	VB	I-VP	O
with	with	IN	B-PP	O
reaction	reaction	NN	B-NP	O
of	of	IN	B-PP	O
elevated	elevated	JJ	B-NP	O
creatinine	creatinine	NN	I-NP	O
at	at	IN	B-PP	O
a	a	DT	B-NP	O
low	low	JJ	I-NP	O
dose	dose	NN	I-NP	O
.	.	.	O	O

To	To	TO	B-PP	O
levofloxacin	levofloxacin	NN	B-NP	O
,	,	,	O	O
she	she	PRP	B-NP	O
has	have	VBZ	B-VP	O
reflux	reflux	NN	B-NP	O
and	and	CC	I-NP	O
celecoxib	celecoxib	NN	I-NP	O
gives	give	VBZ	B-VP	O
her	her	PRP$	B-NP	O
dizziness	dizziness	NN	I-NP	O
and	and	CC	I-NP	O
elevated	elevated	JJ	I-NP	O
creatinine	creatinine	NN	I-NP	O
.	.	.	O	O

BRIEF	BRIEF	NN	B-NP	O
ADMISSION	ADMISSION	NN	I-NP	O
PHYSICAL	PHYSICAL	NN	I-NP	O
EXAMINATION	EXAMINATION	NN	I-NP	O
:	:	:	O	O
She	She	PRP	B-NP	O
had	have	VBD	B-VP	O
a	a	DT	B-NP	O
temperature	temperature	NN	I-NP	O
of	of	IN	B-PP	O
101	101	CD	B-NP	O
,	,	,	O	O
pulse	pulse	NN	B-NP	O
of	of	IN	B-PP	O
106	106	CD	B-NP	O
,	,	,	O	O
blood	blood	NN	B-NP	O
pressure	pressure	NN	I-NP	O
172/71	172/71	CD	I-NP	O
,	,	,	O	O
oxygen	oxygen	NN	B-NP	O
saturation	saturation	NN	I-NP	O
of	of	IN	B-PP	O
100	100	CD	B-NP	O
%	%	NN	I-NP	O
on	on	IN	B-PP	O
room	room	NN	B-NP	O
air	air	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
alert	alert	JJ	B-ADJP	O
and	and	CC	O	O
oriented	orient	VBN	B-VP	O
x3	x3	NN	B-NP	O
,	,	,	O	O
in	in	IN	B-PP	O
mild	mild	JJ	B-NP	O
distress	distress	NN	I-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
lungs	lung	NNS	I-NP	O
were	be	VBD	B-VP	O
clear	clear	JJ	B-ADJP	O
to	to	TO	B-PP	O
auscultation	auscultation	NN	B-NP	O
bilaterally	bilaterally	RB	B-ADVP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
heart	heart	NN	I-NP	O
had	have	VBD	B-VP	O
a	a	DT	B-NP	O
regular	regular	JJ	I-NP	O
rate	rate	NN	I-NP	O
and	and	CC	I-NP	O
rhythm	rhythm	NN	I-NP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
2/6	2/6	CD	I-NP	O
early	early	JJ	I-NP	O
systolic	systolic	JJ	I-NP	O
murmur	murmur	NN	I-NP	O
at	at	IN	B-PP	O
the	the	DT	B-NP	O
left	left	JJ	I-NP	O
lower	low	JJR	I-NP	O
sternal	sternal	JJ	I-NP	O
border	border	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
obese	obese	JJ	B-ADJP	O
,	,	,	O	O
but	but	CC	O	O
had	have	VBD	B-VP	O
a	a	DT	B-NP	O
nontender	nontender	JJ	I-NP	O
,	,	,	I-NP	O
nondistended	nondistended	JJ	I-NP	O
abdomen	abdoman	NNS	I-NP	O
with	with	IN	B-PP	O
normal	normal	JJ	B-NP	O
abdominal	abdominal	JJ	I-NP	O
bowel	bowel	NN	I-NP	O
sounds	sound	NNS	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
guaiac	guaiac	JJ	B-ADJP	O
negative	negative	JJ	I-ADJP	O
,	,	,	O	O
and	and	CC	O	O
her	her	PRP$	B-NP	O
left	left	JJ	I-NP	O
foot	foot	NN	I-NP	O
was	be	VBD	B-VP	O
in	in	IN	B-PP	O
a	a	DT	B-NP	O
cast	cast	NN	I-NP	O
.	.	.	O	O

PERTINENT	PERTINENT	NN	B-NP	O
LABORATORY	LABORATORY	NN	I-NP	O
TESTS	TESTS	NNS	I-NP	O
AND	AND	CC	I-NP	O
RESULTS	RESULTS	NNS	I-NP	O
:	:	:	O	O
She	She	PRP	B-NP	O
had	have	VBD	B-VP	O
a	a	DT	B-NP	O
sodium	sodium	NN	I-NP	O
of	of	IN	B-PP	O
127	127	CD	B-NP	O
,	,	,	O	O
corrected	correct	VBN	B-VP	O
to	to	TO	B-PP	O
131	131	CD	B-NP	O
with	with	IN	B-PP	O
her	her	PRP$	B-NP	O
glucose	glucose	NN	I-NP	O
,	,	,	O	O
potassium	potassium	NN	B-NP	O
of	of	IN	B-PP	O
4.9	4.9	CD	B-NP	O
,	,	,	O	O
bicarbonate	bicarbonate	NN	B-NP	O
of	of	IN	B-PP	O
27	27	CD	B-NP	O
,	,	,	O	O
BUN	BUN	NN	B-NP	B-DNA
95	95	CD	I-NP	I-DNA
,	,	,	O	O
creatinine	creatinine	NN	B-NP	O
4.5	4.5	CD	I-NP	O
,	,	,	O	O
glucose	glucose	NN	B-NP	O
329	329	CD	I-NP	O
.	.	.	O	O

LFTs	LFT	NNS	B-NP	B-protein
were	be	VBD	B-VP	O
normal	normal	JJ	B-ADJP	O
,	,	,	O	O
amylase	amylase	NN	B-NP	B-protein
19	19	CD	I-NP	I-protein
,	,	,	O	O
lipase	lipase	NN	B-NP	O
8	8	CD	I-NP	O
,	,	,	I-NP	O
negative	negative	JJ	I-NP	O
keto	keto	NN	I-NP	O
acids	acid	NNS	I-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
serum	serum	NN	I-NP	O
and	and	CC	I-NP	O
urine	urine	NN	I-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
white	white	JJ	I-NP	O
blood	blood	NN	I-NP	O
count	count	NN	I-NP	O
was	be	VBD	B-VP	O
26.8	26.8	CD	B-NP	O
,	,	,	O	O
INR	INR	NN	B-NP	B-protein
was	be	VBD	B-VP	O
1.4	1.4	CD	B-NP	O
,	,	,	O	O
PTT	PTT	NN	B-NP	O
was	be	VBD	B-VP	O
36.6	36.6	CD	B-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
had	have	VBD	B-VP	O
a	a	DT	B-NP	O
dirty	dirty	JJ	I-NP	O
urinalysis	urinalysis	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
had	have	VBD	B-VP	O
an	an	DT	B-NP	O
abdominal	abdominal	JJ	I-NP	O
CT	CT	NN	I-NP	O
that	that	WDT	B-NP	O
showed	show	VBD	B-VP	O
a	a	DT	B-NP	O
non-incarcerated	non-incarcerated	JJ	I-NP	O
hernia	hernia	NN	I-NP	O
,	,	,	O	O
no	no	DT	B-NP	O
evidence	evidence	NN	I-NP	O
of	of	IN	B-PP	O
colitis	colitis	NN	B-NP	O
.	.	.	O	O

OPERATIONS	OPERATIONS	NNS	B-NP	O
AND	AND	CC	I-NP	O
PROCEDURES	PROCEDURES	NNS	I-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
had	have	VBD	B-VP	O
a	a	DT	B-NP	O
debridement	debridement	NN	I-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
left	left	JJ	I-NP	O
foot	foot	NN	I-NP	O
on	on	IN	B-PP	O
9/25/06	9/25/06	CD	B-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
also	also	RB	B-ADVP	O
had	have	VBD	B-VP	O
hemodialysis	hemodialysis	NN	B-NP	O
initiated	initiate	VBN	B-VP	O
on	on	IN	B-PP	O
10/9/06	10/9/06	CD	B-NP	O
.	.	.	O	O

HOSPITAL	HOSPITAL	NNP	B-NP	O
COURSE	COURSE	NNP	I-NP	O
BY	BY	NNP	I-NP	O
SYSTEMS	SYSTEMS	NNP	I-NP	O
:	:	:	O	O
1	1	CD	B-NP	O
.	.	.	O	O

Infectious	Infectious	JJ	B-NP	O
disease	disease	NN	I-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
left	left	JJ	I-NP	O
foot	foot	NN	I-NP	O
was	be	VBD	B-VP	O
encasted	encaste	VBN	I-VP	O
by	by	IN	B-PP	O
orthopedics	orthopedic	NNS	B-NP	O
surgery	surgery	NN	I-NP	O
on	on	IN	B-PP	O
2/29/06	2/29/06	CD	B-NP	O
with	with	IN	B-PP	O
evidence	evidence	NN	B-NP	O
of	of	IN	B-PP	O
underlying	underlie	VBG	B-VP	O
infection	infection	NN	B-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	B-cell_line
wound	wound	JJ	I-NP	I-cell_line
cultures	culture	NNS	I-NP	I-cell_line
grew	grow	VBD	B-VP	O
MRSA	MRSA	NN	B-NP	O
with	with	IN	B-PP	O
probes	probe	NNS	B-NP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
bone	bone	NN	I-NP	O
.	.	.	O	O

X-rays	X-ray	NNS	B-NP	O
were	be	VBD	B-VP	O
unrevealing	unrevealing	JJ	B-ADJP	O
and	and	CC	O	O
MRI	MRI	NN	B-NP	B-protein
showed	show	VBD	B-VP	O
severe	severe	JJ	B-NP	O
osteomyelitis	osteomyelitis	NN	I-NP	O
.	.	.	O	O

In	In	IN	B-PP	O
addition	addition	NN	B-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
had	have	VBD	B-VP	O
an	an	DT	B-NP	O
ESR	ESR	NN	I-NP	B-protein
of	of	IN	B-PP	O
109	109	CD	B-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
thus	thus	RB	I-VP	O
put	put	VBN	I-VP	O
on	on	IN	B-PP	O
levofloxacin	levofloxacin	NN	B-NP	O
,	,	,	O	O
vancomycin	vancomycin	NN	B-NP	O
,	,	,	O	O
and	and	CC	O	O
Flagyl	Flagyl	NN	B-NP	O
.	.	.	O	O

Blood	Blood	NN	B-NP	B-cell_line
cultures	culture	NNS	I-NP	I-cell_line
from	from	IN	B-PP	O
6/16/06	6/16/06	CD	B-NP	O
additionally	additionally	RB	B-ADVP	O
grew	grow	VBD	B-VP	O
gram-positive	gram-positive	JJ	B-NP	O
cocci	coccus	NNS	I-NP	O
in	in	IN	B-PP	O
clusters	cluster	NNS	B-NP	O
which	which	WDT	B-NP	O
eventually	eventually	RB	B-ADVP	O
yielded	yield	VBD	B-VP	O
MRSA	MRSA	NN	B-NP	O
.	.	.	O	O

However	However	RB	B-ADVP	O
,	,	,	O	O
surveillance	surveillance	NN	B-NP	O
cultures	culture	NNS	I-NP	O
with	with	IN	B-PP	O
treatment	treatment	NN	B-NP	O
on	on	IN	B-PP	O
levofloxacin	levofloxacin	NN	B-NP	O
,	,	,	O	O
vancomycin	vancomycin	NN	B-NP	O
,	,	,	O	O
and	and	CC	O	O
Flagyl	Flagyl	NN	B-NP	O
were	be	VBD	B-VP	O
negative	negative	JJ	B-ADJP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
received	receive	VBD	B-VP	O
debridement	debridement	NN	B-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
left	left	JJ	I-NP	O
foot	foot	NN	I-NP	O
on	on	IN	B-PP	O
9/25/06	9/25/06	CD	B-NP	O
.	.	.	O	O

In	In	IN	B-PP	O
the	the	DT	B-NP	O
OR	OR	NN	I-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
bone	bone	NN	I-NP	O
looked	look	VBD	B-VP	O
necrotic	necrotic	JJ	B-ADJP	O
and	and	CC	I-ADJP	O
infected	infected	JJ	I-ADJP	O
.	.	.	O	O

The	The	DT	B-NP	O
bone	bone	NN	I-NP	O
was	be	VBD	B-VP	O
sent	send	VBN	I-VP	O
to	to	TO	B-PP	O
pathology	pathology	NN	B-NP	O
and	and	CC	I-NP	O
microbiology	microbiology	NN	I-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
results	result	NNS	I-NP	O
of	of	IN	B-PP	O
which	which	WDT	B-NP	O
are	be	VBP	B-VP	O
pending	pende	VBG	B-ADJP	O
.	.	.	O	O

Given	Give	VBN	B-PP	O
the	the	DT	B-NP	O
appearance	appearance	NN	I-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
bone	bone	NN	I-NP	O
during	during	IN	B-PP	O
debridement	debridement	NN	B-NP	O
,	,	,	O	O
it	it	PRP	B-NP	O
is	be	VBZ	B-VP	O
presumed	presume	VBN	I-VP	O
that	that	IN	B-SBAR	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
will	will	MD	B-VP	O
need	need	VB	I-VP	O
eight	eight	CD	B-NP	O
weeks	week	NNS	I-NP	O
of	of	IN	B-PP	O
vancomycin	vancomycin	NN	B-NP	O
.	.	.	O	O

Because	Because	IN	B-SBAR	O
she	she	PRP	B-NP	O
did	do	VBD	B-VP	O
have	have	VB	I-VP	O
a	a	DT	B-NP	O
clear	clear	JJ	I-NP	O
source	source	NN	I-NP	O
of	of	IN	B-PP	O
fevers	fever	NNS	B-NP	O
after	after	IN	B-SBAR	O
it	it	PRP	B-NP	O
was	be	VBD	B-VP	O
found	find	VBN	I-VP	O
that	that	IN	B-SBAR	O
she	she	PRP	B-NP	O
had	have	VBD	B-VP	O
osteomyelitis	osteomyelitis	NN	B-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
discontinued	discontinue	VBN	I-VP	O
off	off	RP	B-PRT	O
Flagyl	Flagyl	NN	B-NP	O
and	and	CC	I-NP	O
levofloxacin	levofloxacin	NN	I-NP	O
on	on	IN	B-PP	O
5/6/06	5/6/06	CD	B-NP	O
.	.	.	O	O

2	2	LS	B-LST	O
.	.	.	O	O

GI	GI	LS	B-LST	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
has	have	VBZ	B-VP	O
abdominal	abdominal	JJ	B-NP	O
pain	pain	NN	I-NP	O
with	with	IN	B-PP	O
gastric	gastric	JJ	B-NP	O
emptying	empty	VBG	I-NP	O
study	study	NN	I-NP	O
on	on	IN	B-PP	O
6/16/06	6/16/06	CD	B-NP	O
showing	show	VBG	B-VP	O
0	0	CD	B-NP	O
%	%	NN	I-NP	O
clearance	clearance	NN	I-NP	O
at	at	IN	B-PP	O
90	90	CD	B-NP	O
minutes	minute	NNS	I-NP	O
consistent	consistent	JJ	B-ADJP	O
with	with	IN	B-PP	O
severe	severe	JJ	B-NP	O
gastroparesis	gastroparesis	NN	I-NP	O
versus	versus	IN	B-PP	O
obstruction	obstruction	NN	B-NP	O
.	.	.	O	O

Radiology	Radiology	NN	B-NP	O
did	do	VBD	B-VP	O
not	not	RB	I-VP	O
feel	feel	VB	I-VP	O
that	that	IN	B-SBAR	O
an	an	DT	B-NP	O
upper	upper	JJ	I-NP	O
GI	GI	NN	I-NP	O
series	series	NN	I-NP	O
would	would	MD	B-VP	O
give	give	VB	I-VP	O
further	further	JJ	B-NP	O
information	information	NN	I-NP	O
regarding	regard	VBG	B-VP	O
obstruction	obstruction	NN	B-NP	O
and	and	CC	O	O
it	it	PRP	B-NP	O
was	be	VBD	B-VP	O
judged	judge	VBN	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
unlikely	unlikely	JJ	B-ADJP	O
given	give	VBN	B-PP	O
that	that	IN	B-SBAR	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
has	have	VBZ	B-VP	O
bowel	bowel	NN	B-NP	O
movements	movement	NNS	I-NP	O
and	and	CC	O	O
rare	rare	JJ	B-NP	O
emesis	emesis	NN	I-NP	O
.	.	.	O	O

Later	Later	RB	B-ADVP	O
on	on	RB	I-ADVP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
hospital	hospital	NN	I-NP	O
course	course	NN	I-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
put	put	VBN	I-VP	O
on	on	IN	B-PP	O
erythromycin	erythromycin	NN	B-NP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
decrease	decrease	NN	I-NP	O
in	in	IN	B-PP	O
her	her	PRP$	B-NP	O
symptoms	symptom	NNS	I-NP	O
of	of	IN	B-PP	O
abdominal	abdominal	JJ	B-NP	O
pain	pain	NN	I-NP	O
,	,	,	O	O
nausea	nausea	NN	B-NP	O
,	,	,	O	O
and	and	CC	O	O
vomiting	vomiting	NN	B-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
did	do	VBD	B-VP	O
have	have	VB	I-VP	O
any	any	DT	B-NP	O
evidence	evidence	NN	I-NP	O
of	of	IN	B-PP	O
bowel	bowel	NN	B-NP	O
ischemia	ischemia	NN	I-NP	O
on	on	IN	B-PP	O
MRA	MRA	NN	B-NP	B-protein
.	.	.	O	O

Later	Later	RB	B-ADVP	O
,	,	,	O	O
erythromycin	erythromycin	NN	B-NP	O
was	be	VBD	B-VP	O
changed	change	VBN	I-VP	O
to	to	TO	I-VP	O
Reglan	Reglan	VB	I-VP	O
on	on	IN	B-PP	O
4/8/06	4/8/06	CD	B-NP	O
per	per	IN	B-PP	O
renal	renal	JJ	B-NP	O
request	request	NN	I-NP	O
during	during	IN	B-PP	O
hemodialysis	hemodialysis	NN	B-NP	O
.	.	.	O	O

There	There	EX	B-NP	O
is	be	VBZ	B-VP	O
no	no	DT	B-NP	O
evidence	evidence	NN	I-NP	O
of	of	IN	B-PP	O
pancreatis	pancreatis	NN	B-NP	O
or	or	CC	O	O
liver	liver	NN	B-NP	O
disease	disease	NN	I-NP	O
and	and	CC	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
also	also	RB	I-VP	O
kept	keep	VBN	I-VP	O
on	on	IN	B-PP	O
Compazine	Compazine	NN	B-NP	O
for	for	IN	B-PP	O
nausea	nausea	NN	B-NP	O
.	.	.	O	O

3	3	LS	B-LST	O
.	.	.	O	O

Renal	Renal	JJ	B-ADJP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
had	have	VBD	B-VP	O
,	,	,	O	O
on	on	IN	B-PP	O
admission	admission	NN	B-NP	O
,	,	,	O	O
acute	acute	JJ	B-ADJP	O
on	on	IN	B-PP	O
chronic	chronic	JJ	B-NP	O
renal	renal	JJ	I-NP	O
failure	failure	NN	I-NP	O
.	.	.	O	O

There	There	EX	B-NP	O
was	be	VBD	B-VP	O
a	a	DT	B-NP	O
concern	concern	NN	I-NP	O
for	for	IN	B-PP	O
prerenal	prerenal	JJ	B-NP	O
azotemia	azotemia	NN	I-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
setting	setting	NN	I-NP	O
of	of	IN	B-PP	O
nausea	nausea	NN	B-NP	O
and	and	CC	I-NP	O
vomiting	vomiting	NN	I-NP	O
and	and	CC	I-NP	O
diarrhea	diarrhea	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
had	have	VBD	B-VP	O
a	a	DT	B-NP	O
fractional	fractional	JJ	I-NP	O
excretion	excretion	NN	I-NP	O
of	of	IN	B-PP	O
sodium	sodium	NN	B-NP	O
which	which	WDT	B-NP	O
was	be	VBD	B-VP	O
0.3	0.3	CD	B-NP	O
%	%	NN	I-NP	O
,	,	,	O	O
but	but	CC	O	O
it	it	PRP	B-NP	O
was	be	VBD	B-VP	O
difficult	difficult	JJ	B-ADJP	O
to	to	TO	B-VP	O
interpret	interpret	VB	I-VP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
setting	setting	NN	I-NP	O
of	of	IN	B-PP	O
end-stage	end-stage	JJ	B-NP	O
renal	renal	JJ	I-NP	O
disease	disease	NN	I-NP	O
.	.	.	O	O

Lasix	Lasix	NNP	B-NP	O
and	and	CC	I-NP	O
Cozaar	Cozaar	NNP	I-NP	O
were	be	VBD	B-VP	O
held	hold	VBN	I-VP	O
.	.	.	O	O

However	However	RB	B-ADVP	O
,	,	,	O	O
the	the	DT	B-NP	O
creatinine	creatinine	NN	I-NP	O
continued	continue	VBD	B-VP	O
to	to	TO	I-VP	O
worsen	worsen	VB	I-VP	O
reaching	reach	VBG	I-VP	O
6.1	6.1	CD	B-NP	O
on	on	IN	B-PP	O
9/14/06	9/14/06	CD	B-NP	O
.	.	.	O	O

Renal	Renal	JJ	B-NP	O
was	be	VBD	B-VP	O
consulted	consult	VBN	I-VP	O
regarding	regard	VBG	B-PP	O
the	the	DT	B-NP	O
need	need	NN	I-NP	O
for	for	IN	B-PP	O
dialysis	dialysis	NN	B-NP	O
.	.	.	O	O

On	On	IN	B-PP	O
admission	admission	NN	B-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
did	do	VBD	B-VP	O
have	have	VB	I-VP	O
matured	mature	VBN	I-VP	O
AV	AV	NN	B-NP	O
fistula	fistula	NN	I-NP	O
graft	graft	NN	I-NP	O
and	and	CC	O	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
thus	thus	RB	I-VP	O
started	start	VBN	I-VP	O
on	on	IN	B-PP	O
hemodialysis	hemodialysis	NN	B-NP	O
on	on	IN	B-PP	O
10/9/06	10/9/06	CD	B-NP	O
.	.	.	O	O

4	4	LS	B-LST	O
.	.	.	O	O

Hematology	Hematology	NN	B-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
had	have	VBD	B-VP	O
an	an	DT	B-NP	O
INR	INR	NN	I-NP	B-protein
which	which	WDT	B-NP	O
was	be	VBD	B-VP	O
elevated	elevate	VBN	I-VP	O
.	.	.	O	O

Hematocrit	Hematocrit	NN	B-NP	O
was	be	VBD	B-VP	O
also	also	RB	I-VP	O
decreased	decrease	VBN	I-VP	O
to	to	TO	B-PP	O
25.5	25.5	CD	B-NP	O
from	from	IN	B-PP	O
34	34	CD	B-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
guaiac	guaiac	JJ	B-ADJP	O
negative	negative	JJ	I-ADJP	O
and	and	CC	O	O
did	do	VBD	B-VP	O
have	have	VB	I-VP	O
any	any	DT	B-NP	O
schistocyte	schistocyte	NN	I-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
LDH	LDH	NN	I-NP	B-protein
was	be	VBD	B-VP	O
also	also	RB	B-ADVP	O
normal	normal	JJ	B-ADJP	O
with	with	IN	B-PP	O
her	her	PRP$	B-NP	O
haptoglobin	haptoglobin	NN	I-NP	O
high	high	JJ	B-ADJP	O
.	.	.	O	O

It	It	PRP	B-NP	O
was	be	VBD	B-VP	O
judged	judge	VBN	I-VP	O
from	from	IN	B-PP	O
her	her	PRP$	B-NP	O
iron	iron	NN	I-NP	O
studies	study	NNS	I-NP	O
that	that	IN	B-SBAR	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
iron	iron	NN	B-NP	O
deficient	deficient	JJ	B-ADJP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
put	put	VBN	I-VP	O
on	on	IN	B-PP	O
iron	iron	NN	B-NP	O
supplementation	supplementation	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
also	also	RB	B-ADVP	O
was	be	VBD	B-VP	O
felt	feel	VBN	I-VP	O
to	to	TO	I-VP	O
have	have	VB	I-VP	O
renal	renal	JJ	B-NP	O
component	component	NN	I-NP	O
to	to	TO	B-PP	O
her	her	PRP$	B-NP	O
anemia	anemia	NN	I-NP	O
and	and	CC	O	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
started	start	VBN	I-VP	O
on	on	IN	B-PP	O
darbepoetin	darbepoetin	NN	B-NP	O
initially	initially	RB	B-ADVP	O
and	and	CC	O	O
changed	change	VBD	B-VP	O
to	to	TO	B-PP	O
erythropoietin	erythropoietin	NN	B-NP	B-protein
later	later	RB	B-ADVP	O
during	during	IN	B-PP	O
dialysis	dialysis	NN	B-NP	O
by	by	IN	B-PP	O
renal	renal	JJ	B-ADJP	O
.	.	.	O	O

5	5	LS	B-LST	O
.	.	.	O	O

Cardiovascular	Cardiovascular	JJ	B-ADJP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
maintained	maintain	VBN	I-VP	O
on	on	IN	B-PP	O
aspirin	aspirin	NN	B-NP	O
,	,	,	O	O
a	a	DT	B-NP	O
statin	statin	NN	I-NP	O
,	,	,	O	O
and	and	CC	O	O
calcium	calcium	NN	B-NP	O
channel	channel	NN	I-NP	O
blocker	blocker	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
started	start	VBD	B-VP	O
prophylactic	prophylactic	JJ	B-NP	O
beta-blocker	beta-blocker	NN	I-NP	O
during	during	IN	B-PP	O
her	her	PRP$	B-NP	O
hospital	hospital	NN	I-NP	O
course	course	NN	I-NP	O
as	as	RB	B-ADVP	O
well	well	RB	I-ADVP	O
.	.	.	O	O

6	6	CD	B-NP	O
.	.	.	O	O

Endocrine	Endocrine	NN	B-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
had	have	VBD	B-VP	O
hemoglobin	hemoglobin	NN	B-NP	B-protein
A1c	A1c	NN	I-NP	O
of	of	IN	B-PP	O
7.8	7.8	CD	B-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
transitioned	transitione	VBN	I-VP	O
to	to	TO	B-PP	O
NPH	NPH	NN	B-NP	B-protein
and	and	CC	I-NP	O
Aspart	Aspart	NN	I-NP	O
during	during	IN	B-PP	O
her	her	PRP$	B-NP	O
hospital	hospital	NN	I-NP	O
stay	stay	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
had	have	VBD	B-VP	O
intermittent	intermittent	JJ	B-NP	O
problems	problem	NNS	I-NP	O
with	with	IN	B-PP	O
hypoglycemia	hypoglycemia	NN	B-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
setting	setting	NN	I-NP	O
of	of	IN	B-PP	O
being	be	VBG	B-VP	O
NPO	NPO	NN	B-NP	B-protein
pending	pende	VBG	B-PP	O
operations	operation	NNS	B-NP	O
and	and	CC	I-NP	O
procedures	procedure	NNS	I-NP	O
;	;	:	O	O
however	however	RB	B-ADVP	O
,	,	,	O	O
her	her	PRP$	B-NP	O
insulin	insulin	NN	I-NP	O
regimen	regimen	NN	I-NP	O
was	be	VBD	B-VP	O
titrated	titrate	VBN	I-VP	O
to	to	TO	B-PP	O
good	good	JJ	B-NP	O
glycemic	glycemic	JJ	I-NP	O
response	response	NN	I-NP	O
.	.	.	O	O

7	7	CD	B-NP	O
.	.	.	O	O

Prophylaxis	Prophylaxis	NN	B-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
kept	keep	VBN	I-VP	O
on	on	IN	B-PP	O
heparin	heparin	NN	B-NP	O
and	and	CC	I-NP	O
Nexium	Nexium	NN	I-NP	O
.	.	.	O	O

8	8	CD	B-NP	O
.	.	.	O	O

Fluids	Fluid	NNS	B-NP	O
,	,	,	O	O
electrolytes	electrolyte	NNS	B-NP	O
,	,	,	O	O
and	and	CC	O	O
nutrition	nutrition	NN	B-NP	O
:	:	:	O	O
Her	Her	PRP$	B-NP	O
IV	IV	CD	I-NP	O
fluids	fluid	NNS	I-NP	O
were	be	VBD	B-VP	O
stopped	stop	VBN	I-VP	O
as	as	IN	B-PP	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
oliguric	oliguric	JJ	B-ADJP	O
and	and	CC	I-ADJP	O
anuric	anuric	JJ	I-ADJP	O
initially	initially	RB	B-ADVP	O
before	before	IN	B-PP	O
hemodialysis	hemodialysis	NN	B-NP	O
.	.	.	O	O

Later	Later	RB	B-ADVP	O
on	on	IN	B-PP	O
,	,	,	O	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
also	also	RB	I-VP	O
put	put	VBN	I-VP	O
on	on	IN	B-PP	O
1500	1500	CD	B-NP	O
mL	mL	NN	I-NP	O
fluid	fluid	NN	I-NP	O
restriction	restriction	NN	I-NP	O
.	.	.	O	O

Later	Later	RB	B-ADVP	O
on	on	IN	B-PP	O
during	during	IN	B-PP	O
dialysis	dialysis	NN	B-NP	O
,	,	,	O	O
her	her	PRP$	B-NP	O
volume	volume	NN	I-NP	O
status	status	NN	I-NP	O
resolved	resolve	VBD	B-VP	O
euvolemia	euvolemia	NN	B-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
kept	keep	VBN	I-VP	O
on	on	IN	B-PP	O
a	a	DT	B-NP	O
low	low	JJ	I-NP	O
fat	fat	NN	I-NP	O
and	and	CC	O	O
low	low	JJ	B-NP	O
cholesterol	cholesterol	NN	I-NP	O
diabetic	diabetic	JJ	I-NP	O
diet	diet	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
is	be	VBZ	B-VP	O
full	full	JJ	B-NP	O
code	code	NN	I-NP	O
.	.	.	O	O

DISCHARGE	DISCHARGE	NN	B-NP	O
MEDICATIONS	MEDICATIONS	NNS	I-NP	O
:	:	:	O	O
1	1	LS	B-LST	O
.	.	.	O	O

Tylenol	Tylenol	NN	B-NP	B-protein
650	650	CD	I-NP	I-protein
mg	mg	NN	I-NP	I-protein
p.o.	p.o.	NN	I-NP	I-protein
q.	q.	NN	I-NP	I-protein
4	4	CD	I-NP	I-protein
.	.	.	O	O

p.r.n.	p.r.n.	LS	B-NP	O
headache	headache	NN	I-NP	O
.	.	.	O	O

2	2	LS	B-LST	O
.	.	.	O	O

Aspirin	Aspirin	NN	B-NP	O
81	81	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	RB	B-ADVP	O
daily	daily	RB	I-ADVP	O
.	.	.	O	O

3	3	LS	B-LST	O
.	.	.	O	O

Colace	Colace	NNP	B-NP	O
100	100	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
b.i.d.	b.i.d.	NN	I-NP	O
4	4	CD	I-NP	O
.	.	.	O	O

Heparin	Heparin	NN	B-NP	B-protein
5000	5000	CD	I-NP	I-protein
units	unit	NNS	I-NP	I-protein
subq	subq	NN	I-NP	I-protein
t.i.d.	t.i.d.	NN	I-NP	I-protein
5	5	CD	I-NP	I-protein
.	.	.	O	O

Dilaudid	Dilaudid	VBD	B-VP	O
0.4-0	0.4-0	CD	B-NP	O
.8	.8	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
q.	q.	NN	I-NP	O
4	4	CD	I-NP	O
.	.	.	O	O

p.r.n.	p.r.n.	LS	B-NP	O
pain	pain	NN	I-NP	O
.	.	.	O	O

6	6	CD	B-NP	O
.	.	.	O	O

Insulin	Insulin	NN	B-NP	B-protein
NPH	NPH	NN	I-NP	I-protein
human	human	JJ	I-NP	I-protein
20	20	CD	I-NP	I-protein
units	unit	NNS	I-NP	I-protein
subq	subq	NN	I-NP	I-protein
b.i.d.	b.i.d.	NN	I-NP	I-protein
7	7	CD	I-NP	I-protein
.	.	.	O	O

Lactulose	Lactulose	RB	B-NP	O
30	30	CD	I-NP	O
mL	mL	NN	I-NP	O
p.o.	p.o.	FW	B-NP	O
q.i.d.	q.i.d.	FW	I-NP	O
p.r.n.	p.r.n.	NN	I-NP	O
constipation	constipation	NN	I-NP	O
.	.	.	O	O

8	8	CD	B-NP	O
.	.	.	O	O

Reglan	Reglan	NN	B-NP	O
5	5	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
q.a.c.	q.a.c.	NN	I-NP	O
9	9	CD	I-NP	O
.	.	.	O	O

Reglan	Reglan	NN	B-NP	O
5	5	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
q.h.s.	q.h.s.	NN	I-NP	O
10	10	CD	I-NP	O
.	.	.	O	O

Lopressor	Lopressor	NN	B-NP	O
50	50	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
q.i.d.	q.i.d.	NN	I-NP	O
11	11	CD	I-NP	O
.	.	.	O	O

Senna	Senna	NNP	B-NP	O
tablets	tablet	VBZ	B-VP	O
two	two	CD	B-NP	O
tabs	tab	NNS	I-NP	O
p.o.	p.o.	FW	B-PP	O
b.i.d.	b.i.d.	NN	B-NP	O
12	12	CD	I-NP	O
.	.	.	O	O

Norvasc	Norvasc	NN	B-NP	O
10	10	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	RB	B-ADVP	O
daily	daily	RB	I-ADVP	O
.	.	.	O	O

13	13	CD	B-NP	O
.	.	.	O	O

Compazine	Compazine	NN	B-NP	O
5-10	5-10	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
q.	q.	NN	I-NP	O
6h	6h	NN	I-NP	O
.	.	.	O	O

p.r.n.	p.r.n.	LS	B-NP	O
nausea	nausea	NN	I-NP	O
.	.	.	O	O

14	14	CD	B-NP	O
.	.	.	O	O

Nephrocaps	Nephrocaps	RB	B-NP	O
one	one	CD	I-NP	O
tab	tab	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
daily	daily	RB	B-ADVP	O
.	.	.	O	O

15	15	CD	B-NP	O
.	.	.	O	O

Insulin	Insulin	NNP	B-NP	O
Aspart	Aspart	NNP	I-NP	O
sliding	slide	VBG	B-VP	O
scale	scale	NN	B-NP	O
subq	subq	NN	I-NP	O
a.c.	a.c.	RB	B-NP	O
16	16	CD	I-NP	O
.	.	.	O	O

Insulin	Insulin	NN	B-NP	O
Aspart	Aspart	NN	I-NP	O
4	4	CD	B-NP	O
units	unit	NNS	I-NP	O
subq	subq	NN	I-NP	O
q.a.c.	q.a.c.	NN	I-NP	O
17	17	CD	I-NP	O
.	.	.	O	O

Lipitor	Lipitor	NN	B-NP	O
80	80	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	RB	B-ADVP	O
daily	daily	RB	I-ADVP	O
.	.	.	O	O

18	18	CD	B-NP	O
.	.	.	O	O

Protonix	Protonix	NNP	B-NP	O
40	40	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	RB	B-ADVP	O
daily	daily	RB	I-ADVP	O
.	.	.	O	O

19	19	CD	B-NP	O
.	.	.	O	O

Vancomycin	Vancomycin	NN	B-NP	O
1	1	CD	I-NP	O
g	g	NN	I-NP	O
IV	IV	CD	B-NP	O
three	three	CD	I-NP	O
times	time	NNS	I-NP	O
a	a	DT	B-NP	O
week	week	NN	I-NP	O
.	.	.	O	O

These	These	DT	B-NP	O
doses	dose	NNS	I-NP	O
are	be	VBP	B-VP	O
all	all	DT	O	O
to	to	TO	B-VP	O
be	be	VB	I-VP	O
given	give	VBN	I-VP	O
during	during	IN	B-PP	O
hemodialysis	hemodialysis	NN	B-NP	O
.	.	.	O	O

20	20	CD	B-NP	O
.	.	.	O	O

Ergocalciferol	Ergocalciferol	NN	B-NP	O
50	50	CD	I-NP	O
,	,	,	I-NP	O
000	000	CD	I-NP	O
units	unit	NNS	I-NP	O
p.o.	p.o.	FW	I-NP	O
q.	q.	NN	I-NP	O
week	week	NN	I-NP	O
for	for	IN	B-PP	O
six	six	CD	B-NP	O
weeks	week	NNS	I-NP	O
.	.	.	O	O

eScription	eScription	NN	B-NP	O
document	document	NN	I-NP	O
:	:	:	O	O
0-9788070	0-9788070	CD	B-NP	O
EMSSten	EMSSten	NNP	I-NP	O
Tel	Tel	NNP	I-NP	O
Dictated	Dictated	NNP	I-NP	O
By	By	NNP	I-NP	O
:	:	:	O	O
NADOLNY	NADOLNY	NNP	B-NP	O
,	,	,	O	O
SANG	SANG	NNP	B-NP	O
Attending	Attending	NNP	I-NP	O
:	:	:	O	O
UNSWORTH	UNSWORTH	NNP	B-NP	O
,	,	,	O	O
OTTO	OTTO	NNP	B-NP	O
Dictation	Dictation	NNP	I-NP	O
ID	ID	NNP	I-NP	O
0109534	0109534	CD	I-NP	O
D	D	NNP	I-NP	O
:	:	:	O	O
5/5/06	5/5/06	CD	B-NP	O
T	T	NN	I-NP	O
:	:	:	O	O
5/5/06	5/5/06	CD	B-NP	O

